Market Overview

ACADIA Pharma Shares Move Higher as JMP Boosted Price Target from $16 to $27

Related ACAD
Benzinga's Volume Movers
ACADIA Pharmaceuticals Announces Stephen Davis As Executive VP, CFO And Chief Business Officer

JMP Securities maintains ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) with a Market Outperform and raises the price target from $16.00 to $27.00.

The stock has opened up more than 4 percent higher. With the stock last trading at $19.45, the firm's new price target implies potential upside of about 39 percent.

Latest Ratings for ACAD

May 2014JP MorganInitiates Coverage onOverweight
Aug 2013McNicoll Lewis VlakDowngradesBuyHold
Jun 2013JMP SecuritiesMaintainsMarket Outperform

View More Analyst Ratings for ACAD
View the Latest Analyst Ratings

Posted-In: News Price Target Analyst Ratings


Related Articles (ACAD)

Around the Web, We're Loving...

Get Benzinga's Newsletters